These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2504599)

  • 1. Intraperitoneal penetration of cefpirome.
    Kavi J; Ashby JP; Wise R; Donovan IA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):556-8. PubMed ID: 2504599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cefpirome (HR 810). A new broad spectrum cephalosporin].
    Bryskier A; Chantot JF
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):477-81. PubMed ID: 3937123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin.
    Kavi J; Andrews JM; Ashby JP; Hillman G; Wise R
    J Antimicrob Chemother; 1988 Dec; 22(6):911-6. PubMed ID: 3243739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.
    Paradis D; Vallée F; Allard S; Bisson C; Daviau N; Drapeau C; Auger F; LeBel M
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2085-92. PubMed ID: 1444289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antibacterial activity of cefpirome in combination with 4 aminoglycosides and 2 fluoroquinolones].
    Le Noc P; Croize J; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):762-7. PubMed ID: 3141888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.
    Sauermann R; Delle-Karth G; Marsik C; Steiner I; Zeitlinger M; Mayer-Helm BX; Georgopoulos A; Müller M; Joukhadar C
    Antimicrob Agents Chemother; 2005 Feb; 49(2):650-5. PubMed ID: 15673747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis.
    Eng RH; Cherubin CE; Smith SM; Buccini F; Harris R
    J Antimicrob Chemother; 1989 Mar; 23(3):373-81. PubMed ID: 2499565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin].
    Chantot JF; Bryskier A
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):482-6. PubMed ID: 3937124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients.
    Zeitlinger MA; Marsik C; Georgopoulos A; Müller M; Heinz G; Joukhadar C
    Int J Antimicrob Agents; 2003 Jun; 21(6):562-7. PubMed ID: 12791470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges.
    Nix DE; Wilton JH; Velasquez N; Budny JL; Lassman HB; Mitchell P; Divan K; Schentag JJ
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():51-7. PubMed ID: 1601757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal penetration of cefotetan.
    Wise R; Donovan IA; Drumm J; Dent J; Bennett SA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):279-81. PubMed ID: 6579881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefpirome clinical pharmacokinetics.
    Strenkoski LC; Nix DE
    Clin Pharmacokinet; 1993 Oct; 25(4):263-73. PubMed ID: 8261711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of cefpirome compared with that of other agents.
    Raizes EG; Cantey JR
    J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients.
    Ikawa K; Morikawa N; Matsuda S; Ikeda K; Ohge H; Takesue Y; Sueda T
    Int J Antimicrob Agents; 2007 Oct; 30(4):352-5. PubMed ID: 17644344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefpirome compared with other third generation cephalosporins against nosocomial isolates in Argentina.
    Casellas JM; Goldberg M; Orellana N; Morosini MI; Negri MC; Arduino S
    Infection; 1990; 18(3):193-5. PubMed ID: 2114372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory and bactericidal activity of cefpirome and cefotaxime against blood culture isolates.
    Ansorg R; Primavesi CA; von Recklinghausen G
    Chemotherapy; 1990; 36(1):24-8. PubMed ID: 2106417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on antibacterial activity of flomoxef and its distribution to serum and intraperitoneal exudate in surgery].
    Yokoyama T; Kodama T; Takesue Y; Fujimoto M; Hiyama E; Ichikawa T
    Jpn J Antibiot; 1987 Oct; 40(10):1809-19. PubMed ID: 3444022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meningeal diffusion of cefpirome in adults].
    Chavanet P; Pechinot A; Waldner-Combernoux A; Kazmierczak A; Portier H
    Pathol Biol (Paris); 1989 May; 37(5):442-5. PubMed ID: 2780101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of cefpirome--rationale for a twelve-hour dosing regimen.
    Craig WA
    Scand J Infect Dis Suppl; 1993; 91():33-40. PubMed ID: 8290901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.
    Joukhadar C; Klein N; Mayer BX; Kreischitz N; Delle-Karth G; Palkovits P; Heinz G; Müller M
    Crit Care Med; 2002 Jul; 30(7):1478-82. PubMed ID: 12130965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.